Pcor: a New Design of Plasmid Vectors for Nonviral Gene Therapy
Gene Therapy (1999) 6, 1482–1488 1999 Stockton Press All rights reserved 0969-7128/99 $12.00 http://www.stockton-press.co.uk/gt BRIEF COMMUNICATION pCOR: a new design of plasmid vectors for nonviral gene therapy F Soubrier, B Cameron, B Manse, S Somarriba, C Dubertret, G Jaslin, G Jung, C Le Caer, D Dang, JM Mouvault, D Scherman, JF Mayaux and J Crouzet Rhoˆne-Poulenc Rorer, Centre de Recherche de Vitry Alfortville, 13 Quai J Guesde, 94403 Vitry-sur-Seine, France A totally redesigned host/vector system with improved initiator protein, protein, encoded by the pir gene limiting properties in terms of safety has been developed. The its host range to bacterial strains that produce this trans- pCOR plasmids are narrow-host range plasmid vectors for acting protein; (2) the plasmid’s selectable marker is not an nonviral gene therapy. These plasmids contain a con- antibiotic resistance gene but a gene encoding a bacterial ditional origin of replication and must be propagated in a suppressor tRNA. Optimized E. coli hosts supporting specifically engineered E. coli host strain, greatly reducing pCOR replication and selection were constructed. High the potential for propagation in the environment or in yields of supercoiled pCOR monomers were obtained (100 treated patients. The pCOR backbone has several features mg/l) through fed-batch fermentation. pCOR vectors carry- that increase safety in terms of dissemination and selec- ing the luciferase reporter gene gave high levels of lucifer- tion: (1) the origin of replication requires a plasmid-specific ase activity when injected into murine skeletal muscle. Keywords: gene therapy; plasmid DNA; conditional replication; selection marker; multimer resolution Two different types of DNA vehicles, based criteria.4 These high copy number plasmids carry a mini- on recombinant viruses and bacterial DNA plasmids, are mal amount of bacterial sequences, a conditional origin used in gene therapy.
[Show full text]